-
Something wrong with this record ?
IgG4-Related Sclerosing Cholangitis: Rarely Diagnosed, but not a Rare Disease
S. Drazilova, E. Veseliny, PD. Lenartova, D. Drazilova, J. Gazda, I. Grgurevic, M. Janicko, P. Jarcuska
Language English Country Egypt
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 1987
Directory of Open Access Journals
from 2014
Free Medical Journals
from 2005 to 1 year ago
PubMed Central
from 2014
Europe PubMed Central
from 2014
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 1987-01-01
Open Access Digital Library
from 1987-01-01
Open Access Digital Library
from 2014-01-01
Medline Complete (EBSCOhost)
from 2014-01-01
Health & Medicine (ProQuest)
from 2013-01-01
Wiley-Blackwell Open Access Titles
from 1987
ROAD: Directory of Open Access Scholarly Resources
from 2014
PubMed
34970512
DOI
10.1155/2021/1959832
Knihovny.cz E-resources
- MeSH
- Diagnosis, Differential MeSH
- Immunoglobulin G MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Bile Duct Neoplasms * diagnosis MeSH
- Cholangitis, Sclerosing * diagnosis MeSH
- Rare Diseases MeSH
- Bile Ducts, Intrahepatic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
IgG4-related sclerosing cholangitis, a biliary manifestation of an IgG4-related disease, belongs to the spectrum of sclerosing cholangiopathies which result in biliary stenosis. It presents with signs of cholestasis and during differential diagnosis it should be distinguished from cholangiocarcinoma or from other forms of sclerosing cholangitis (primary and secondary sclerosing cholangitis). Despite increasing information and recently established diagnostic criteria, IgG4-related sclerosing cholangitis remains underdiagnosed in routine clinical practice. The diagnosis is based on a combination of the clinical picture, laboratory parameters, histological findings, and a cholangiogram. Increased serum IgG4 levels are nonspecific but are indeed a part of the diagnostic criteria proposed by the Japan Biliary Association and the HISORt criteria for IgG4-SC. High serum IgG4 retains clinical utility depending on the magnitude of elevation. Approximately 90% of patients have concomitant autoimmune pancreatitis, while 10% present with isolated biliary involvement only. About 26% of patients have other organ involvement, such as IgG4-related dacryoadenitis/sialadenitis, IgG4-related retroperitoneal fibrosis, or IgG4-related renal lesions. A full-blown histological finding characterized by IgG4-enriched lymphoplasmacytic infiltrates, obliterative phlebitis, and storiform fibrosis is difficult to capture in practice because of its subepithelial localization. However, the histological yield is increased by immunohistochemistry, with evidence of IgG4-positive plasma cells. Based on a cholangiogram, IgG-4 related sclerosing cholangitis is classified into four subtypes according to the localization of stenoses. The first-line treatment is corticosteroids. The aim of the initial treatment is to induce clinical and laboratory remission and cholangiogram normalization. Even though 30% of patients have a recurrent course, in the literature data, there is no consensus on chronic immunosuppressive maintenance therapy. The disease has a good prognosis when diagnosed early.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011661
- 003
- CZ-PrNML
- 005
- 20220506131459.0
- 007
- ta
- 008
- 220425s2021 ua f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2021/1959832 $2 doi
- 035 __
- $a (PubMed)34970512
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ua
- 100 1_
- $a Drazilova, Sylvia $u 2 Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia $1 https://orcid.org/0000000324486757
- 245 10
- $a IgG4-Related Sclerosing Cholangitis: Rarely Diagnosed, but not a Rare Disease / $c S. Drazilova, E. Veseliny, PD. Lenartova, D. Drazilova, J. Gazda, I. Grgurevic, M. Janicko, P. Jarcuska
- 520 9_
- $a IgG4-related sclerosing cholangitis, a biliary manifestation of an IgG4-related disease, belongs to the spectrum of sclerosing cholangiopathies which result in biliary stenosis. It presents with signs of cholestasis and during differential diagnosis it should be distinguished from cholangiocarcinoma or from other forms of sclerosing cholangitis (primary and secondary sclerosing cholangitis). Despite increasing information and recently established diagnostic criteria, IgG4-related sclerosing cholangitis remains underdiagnosed in routine clinical practice. The diagnosis is based on a combination of the clinical picture, laboratory parameters, histological findings, and a cholangiogram. Increased serum IgG4 levels are nonspecific but are indeed a part of the diagnostic criteria proposed by the Japan Biliary Association and the HISORt criteria for IgG4-SC. High serum IgG4 retains clinical utility depending on the magnitude of elevation. Approximately 90% of patients have concomitant autoimmune pancreatitis, while 10% present with isolated biliary involvement only. About 26% of patients have other organ involvement, such as IgG4-related dacryoadenitis/sialadenitis, IgG4-related retroperitoneal fibrosis, or IgG4-related renal lesions. A full-blown histological finding characterized by IgG4-enriched lymphoplasmacytic infiltrates, obliterative phlebitis, and storiform fibrosis is difficult to capture in practice because of its subepithelial localization. However, the histological yield is increased by immunohistochemistry, with evidence of IgG4-positive plasma cells. Based on a cholangiogram, IgG-4 related sclerosing cholangitis is classified into four subtypes according to the localization of stenoses. The first-line treatment is corticosteroids. The aim of the initial treatment is to induce clinical and laboratory remission and cholangiogram normalization. Even though 30% of patients have a recurrent course, in the literature data, there is no consensus on chronic immunosuppressive maintenance therapy. The disease has a good prognosis when diagnosed early.
- 650 12
- $a nádory žlučových cest $x diagnóza $7 D001650
- 650 _2
- $a žlučové cesty intrahepatální $7 D001653
- 650 12
- $a sklerozující cholangitida $x diagnóza $7 D015209
- 650 _2
- $a diferenciální diagnóza $7 D003937
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoglobulin G $7 D007074
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a vzácné nemoci $7 D035583
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Veseliny, Eduard $u 2 Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia $1 https://orcid.org/0000000182567470
- 700 1_
- $a Lenartova, Patricia Denisa $u Department of Infectology and Travel Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Rastislavova 43, 040 01 Kosice, Slovakia $1 https://orcid.org/0000000345380679
- 700 1_
- $a Drazilova, Dagmar $u 1 Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08 Nove Mesto, Prague, Czech Republic $1 https://orcid.org/0000000192330602
- 700 1_
- $a Gazda, Jakub $u 2 Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia $1 https://orcid.org/0000000322462217
- 700 1_
- $a Grgurevic, Ivica $u Department of Gastroenterology, Hepatology and Clinical Nutrition, University of Zagreb School of Medicine and University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia $1 https://orcid.org/0000000305203483
- 700 1_
- $a Janicko, Martin $u 2 Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia $1 https://orcid.org/0000000233293968
- 700 1_
- $a Jarcuska, Peter $u 2 Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia $1 https://orcid.org/0000000161699984 $7 xx0073932
- 773 0_
- $w MED00198695 $t Canadian journal of gastroenterology & hepatology $x 2291-2797 $g Roč. 2021, č. - (2021), s. 1959832
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34970512 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506131451 $b ABA008
- 999 __
- $a ok $b bmc $g 1789325 $s 1162859
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 2021 $c - $d 1959832 $e 20211221 $i 2291-2797 $m Canadian journal of gastroenterology & hepatology $n Can J Gastroenterol Hepatol $x MED00198695
- LZP __
- $a Pubmed-20220425